Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Khan Website

Javed Khan, M.D.

Selected Publications

1)  Orentas RJ, Nordlund J, He J, Sindiri S, Mackall C, Fry TJ, Khan J.
Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.
Front Oncol. 4: 134, 2014.
[Journal]
2)  Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J.
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Cancer Discov. 4: 216-31, 2014.
[Journal]
3)  Shah N, Wang J, Selich-Anderson J, Graham G, Siddiqui H, Li X, Khan J, Toretsky J.
PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-cis Retinoic Acid-Mediated Differentiation in Neuroblastoma.
Clin. Cancer Res. 2014.
[Journal]
4)  Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, Kim JS, Lopez Guerrero JA, Machado I, Wai DH, Picci P, Triche T, Horvai AE, Miettinen M, Wei JS, Catchpool D, Llombart-Bosch A, Waldman T, Khan J.
The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation.
PLoS Genet. 10: e1004475, 2014.
[Journal]
5)  Metaferia B, Wei JS, Song YK, Evangelista J, Aschenbach K, Johansson P, Wen X, Chen Q, Lee A, Hempel H, Gheeya JS, Getty S, Gomez R, Khan J.
Development of peptide nucleic acid probes for detection of the HER2 oncogene.
PLoS ONE. 8: e58870, 2013.
[Journal]
6)  Abdul-Karim R, Berkman BE, Wendler D, Rid A, Khan J, Badgett T, Hull SC.
Disclosure of incidental findings from next-generation sequencing in pediatric genomic research.
Pediatrics. 131: 564-71, 2013.
[Journal]
7)  Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI.
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorg. Med. Chem. Lett. 23: 4398-403, 2013.
[Journal]
8)  Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ.
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
Oncogene. 32: 5429-38, 2013.
[Journal]
9)  Wei JS, Johansson P, Chen L, Song YK, Tolman C, Li S, Hurd L, Patidar R, Wen X, Badgett TC, Cheuk AT, Marshall JC, Steeg PS, Vaqué Díez JP, Yu Y, Gutkind JS, Khan J.
Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma.
PLoS ONE. 8: e77731, 2013.
[Journal]
10)  Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.
Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534).
PLoS ONE. 8: e76551, 2013.
[Journal]
11)  Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, London WB, Moyer Y, Gastier-Foster JM, Smith MA, Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM.
The genetic landscape of high-risk neuroblastoma.
Nat. Genet. 45: 279-84, 2013.
[Journal]
12)  Zhou Q, Lee GS, Brady J, Datta S, Katan M, Sheikh A, Martins MS, Bunney TD, Santich BH, Moir S, Kuhns DB, Long Priel DA, Ombrello A, Stone D, Ombrello MJ, Khan J, Milner JD, Kastner DL, Aksentijevich I.
A hypermorphic missense mutation in PLCG2, encoding phospholipase C?2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.
Am. J. Hum. Genet. 91: 713-20, 2012.
[Journal]
13)  Ren L, Hong SH, Chen QR, Briggs J, Cassavaugh J, Srinivasan S, Lizardo MM, Mendoza A, Xia AY, Avadhani N, Khan J, Khanna C.
Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma.
Cancer Res. 72: 1001-12, 2012.
[Journal]
14)  Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei JS, Marquez VE, Bates SE, Jin Q, Khan J, Ge K, Thiele CJ.
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Cancer Res. 72: 315-24, 2012.
[Journal]
15)  Stauffer JK, Orentas RJ, Lincoln E, Khan T, Salcedo R, Hixon JA, Back TC, Wei JS, Patidar R, Song Y, Hurd L, Tsokos M, Lai EW, Eisenhofer G, Weiss W, Khan J, Wigginton JM.
High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.
Cancer Invest. 30: 343-63, 2012.
[Journal]
16)  Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J.
Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.
Front Oncol. 2: 194, 2012.
[Journal]
17)  Wan X, Yeung C, Kim SY, Dolan JG, Ngo VN, Burkett S, Khan J, Staudt LM, Helman LJ.
Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma.
Cancer Res. 72: 5889-99, 2012.
[Journal]
18)  Dave H, Anver MR, Butcher DO, Brown P, Khan J, Wayne AS, Baskar S, Rader C.
Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.
PLoS ONE. 7: e52655, 2012.
[Journal]
19)  Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD.
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.
Br. J. Cancer. 107: 1418-22, 2012.
[Journal]
20)  Tsang PS, Cheuk AT, Chen QR, Song YK, Badgett TC, Wei JS, Khan J.
Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma.
BMC Cancer. 12: 101, 2012.
[Journal]
21)  Briggs JW, Ren L, Nguyen R, Chakrabarti K, Cassavaugh J, Rahim S, Bulut G, Zhou M, Veenstra TD, Chen Q, Wei JS, Khan J, Uren A, Khanna C.
The ezrin metastatic phenotype is associated with the initiation of protein translation.
Neoplasia. 14: 297-310, 2012.
[Journal]
22)  Briggs J, Paoloni M, Chen QR, Wen X, Khan J, Khanna C.
A compendium of canine normal tissue gene expression.
PLoS ONE. 6: e17107, 2011.
[Journal]
23)  Liu Z, Yang X, Li Z, McMahon C, Sizer C, Barenboim-Stapleton L, Bliskovsky V, Mock B, Ried T, London WB, Maris J, Khan J, Thiele CJ.
CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression.
Cell Death Differ. 18: 1174-83, 2011.
[Journal]
24)  Gonzalez-Bosquet J, Calcei J, Wei JS, Garcia-Closas M, Sherman ME, Hewitt S, Vockley J, Lissowska J, Yang HP, Khan J, Chanock S.
Detection of somatic mutations by high-resolution DNA melting (HRM) analysis in multiple cancers.
PLoS ONE. 6: e14522, 2011.
[Journal]
25)  Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ.
Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Neoplasia. 13: 145-53, 2011.
[Journal]
26)  Guo X, Chen QR, Song YK, Wei JS, Khan J.
Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status.
BMC Med Genomics. 4: 35, 2011.
[Journal]
27)  Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ.
Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
J. Natl. Cancer Inst. 103: 962-78, 2011.
[Journal]
28)  Meadors JL, Cui Y, Chen Q, Song YK, Khan J, Merlino G, Tsokos M, Orentas RJ, Mackall CL.
Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.
Pediatr Blood Cancer. 57: 921-9, 2011.
[Journal]
29)  Chen QR, Yu LR, Tsang P, Wei JS, Song YK, Cheuk A, Chung JY, Hewitt SM, Veenstra TD, Khan J.
Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a.
J. Proteome Res. 10: 479-87, 2011.
[Journal]
30)  Kohler ME, Hallett WH, Chen QR, Khan J, Johnson BD, Orentas RJ.
Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine.
Cell. Immunol. 265: 65-73, 2010.
[Journal]
31)  Gheeya J, Johansson P, Chen QR, Dexheimer T, Metaferia B, Song YK, Wei JS, He J, Pommier Y, Khan J.
Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor.
Cancer Lett. 293: 124-31, 2010.
[Journal]
32)  Metaferia BB, Rittler M, Gheeya JS, Lee A, Hempel H, Plaza A, Stetler-Stevenson WG, Bewley CA, Khan J.
Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry.
Bioorg. Med. Chem. Lett. 20: 7337-40, 2010.
[Journal]
33)  Kohler ME, Johnson BD, Palen K, Chen Q, Khan J, Orentas RJ.
Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data.
Cancer Sci. 101: 2316-24, 2010.
[Journal]
34)  Nishijo K, Chen QR, Zhang L, McCleish AT, Rodriguez A, Cho MJ, Prajapati SI, Gelfond JA, Chisholm GB, Michalek JE, Aronow BJ, Barr FG, Randall RL, Ladanyi M, Qualman SJ, Rubin BP, LeGallo RD, Wang C, Khan J, Keller C.
Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma.
Cancer Res. 69: 2902-11, 2009.
[Journal]
35)  Chen Q, Song YK, Yu L, Wei JS, Chung J, Hewitt SM, Veenstra TD, Khan J.
Global Genomic and Proteomic Analysis Identifies Biological Pathways Related to High-Risk Neuroblastoma.
J. Proteome Res. 9: 373-82, 2009.
[Journal]
36)  Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ, Khan J.
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
J. Clin. Invest. 119: 3395-407, 2009.
[Journal]
37)  Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM.
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.
Br. J. Cancer. 100: 1471-82, 2009.
[Journal]
38)  Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, Cheuk AT, Smith MA, Houghton P, Morton C, Khan J.
microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies.
Clin. Cancer Res. 15: 5560-8, 2009.
[Journal]
39)  Vasudevan SA, Shang X, Chang S, Ge N, Diaz-Miron JL, Russell HV, Hicks MJ, Ludwig AD, Wesson CL, Burlingame SM, Kim ES, Khan J, Yang J, Nuchtern JG.
Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma.
Mol. Cancer Ther. 8: 2478-89, 2009.
[Journal]
40)  Gheeya JS, Chen QR, Benjamin CD, Cheuk AT, Tsang P, Chung JY, Metaferia BB, Badgett TC, Johansson P, Wei JS, Hewitt SM, Khan J.
Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma.
Cancer Biol. Ther. 8, 2009.
[Journal]
41)  Chen Q, Song YK, Wei JS, Bilke S, Asgharzadeh S, Seeger RC, Khan J.
An integrated cross-platform prognosis study on neuroblastoma patients.
Genomics. 92: 195-203, 2008.
[Journal]
42)  Alabran JL, Cheuk A, Liby K, Sporn M, Khan J, Letterio J, Leskov KS.
Human Neuroblastoma Cells Rapidly Enter Cell Cycle Arrest and Apoptosis Following Exposure to C-28 derivatives of the Synthetic Triterpenoid CDDO.
Cancer Biol. Ther. 7, 2008.
[Journal]
43)  Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ.
Molecular characterization of the pediatric preclinical testing panel.
Clin. Cancer Res. 14: 4572-83, 2008.
[Journal]
44)  Wei JS, Badgett TC, Khan J.
New Technologies for Diagnosing Pediatric Tumors Expert Opinion on Medical Diagnostics.
Expert Opin Med Diagn. 2: 1205-1219, 2008.
[Journal]
45)  Kowalska A, Brunner B, Bozsaky E, Chen Q, Stock C, Lorch T, Khan J, Ambros PF.
Sequence based high resolution chromosomal CGH.
Cytogenet. Genome Res. 121: 1-6, 2008.
[Journal]
46)  Wei JS, Song YK, Durinck S, Chen Q, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J, Khan J.
The MYCN oncogene is a direct target of miR-34a.
Oncogene. 27: 5204-13, 2008.
[Journal]
47)  Bilke S, Chen QR, Wei JS, Khan J.
Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification.
Clin. Cancer Res. 14: 5540-7, 2008.
[Journal]
48)  Bilke S, Khan J.
Analysis of comparative genomic hybridization data on cDNA microarrays.
Methods Mol. Biol. 377: 175-86, 2007.
[Journal]
49)  Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, Wei JS, Smith MA, Houghton P, Morton C, Reynolds CP, Lock R, Gorlick R, Khanna C, Thiele CJ, Takikita M, Catchpoole D, Hewitt SM, Khan J.
Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis.
Cancer Res. 67: 32-40, 2007.
[Journal]
50)  Chen Q, Vansant G, Oades K, Pickering M, Wei JS, Song YK, Monforte J, Khan J.
Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction.
J Mol Diagn. 9: 80-8, 2007.
[Journal]
51)  Catchpoole D, Lail A, Guo D, Chen Q, Khan J.
Gene expression profiles that segregate patients with childhood acute lymphoblastic leukaemia: An independent validation study identifies that endoglin associates with patient outcome.
Leuk Res. 31(12): 1741-7, 2007.
[Journal]
52)  Westermann F, Henrich KO, Wei JS, Lutz W, Fischer M, König R, Wiedemeyer R, Ehemann V, Brors B, Ernestus K, Leuschner I, Benner A, Khan J, Schwab M.
High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Clin. Cancer Res. 13: 4695-703, 2007.
[Journal]
53)  Greer B, Khan J.
Online analysis of microarray data using artificial neural networks.
Methods Mol. Biol. 377: 61-74, 2007.
[Journal]
54)  Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD, Orentas RJ.
Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen.
BMC Immunol. 8: 4, 2007.
[Journal]
55)  Chen Q, Bilke S, Wei JS, Greer BT, Steinberg SM, Westermann F, Schwab M, Khan J.
Increased WSB1 copy number correlates with its over-expression which associates with increased survival in neuroblastoma.
Genes Chromosomes Cancer. 45(9): 856-62, 2006.
[Journal]
56)  Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, Oberthuer A, Berthold F, Wei JS, Khan J, Schwab M, Westermann F.
Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
Clin. Cancer Res. 12: 131-8, 2006.
[Journal]
57)  Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA.
The pediatric preclinical testing program: Description of models and early testing results.
Pediatr Blood Cancer. 49(7): 928-40, 2006.
[Journal]
58)  Krasnoselsky AL, Whiteford CC, Wei JS, Bilke S, Westermann F, Chen QR, Khan J.
Altered expression of cell cycle genes distinguishes aggressive neuroblastoma.
Oncogene. 24: 1533-41, 2005.
[Journal]
59)  Wei JS, Whiteford CC, Cenacchi N, Son CG, Khan J.
BBC3 mediates fenretinide-induced cell death in neuroblastoma.
Oncogene. 24(54): 7976-83, 2005.
[Journal]
60)  Son CG, Bilke S, Davis S, Greer BT, Wei JS, Whiteford CC, Chen QR, Cenacchi N, Khan J.
Database of mRNA gene expression profiles of multiple human organs.
Genome Res. 15: 443-50, 2005.
[Journal]
61)  Bilke S, Chen QR, Whiteford CC, Khan J.
Detection of low level genomic alterations by comparative genomic hybridization based on cDNA micro-arrays.
Bioinformatics. 21: 1138-45, 2005.
[Journal]
62)  Kim HS, Choi EH, Khan J, Roilides E, Francesconi A, Kasai M, Sein T, Schaufele RL, Sakurai K, Son CG, Greer BT, Chanock S, Lyman CA, Walsh TJ.
Expression of genes encoding innate host defense molecules in normal human monocytes in response to Candida albicans.
Infect Immun. 73: 3714-24, 2005.
[Journal]
63)  Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J.
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.
Clin. Cancer Res. 11: 6300-10, 2005.
[Journal]
64)  Chen Q, Bilke S, Khan J.
High-resolution cDNA microarray-based comparative genomic hybridization analysis in neuroblastoma.
Cancer Lett. 228(1-2): 71-81, 2005.
[Journal]
65)  Bilke S, Chen QR, Westerman F, Schwab M, Catchpoole D, Khan J.
Inferring a tumor progression model for neuroblastoma from genomic data.
J. Clin. Oncol. 23: 7322-31, 2005.
[Journal]
66)  Umar A, Kapetanovic I, Khan J, eds.
The Applications of Bioinformatics in Cancer Detection. Volume 1020.
New York: The New York Academy of Sciences; 2004. [Book (Editor)]
67)  Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, Greer BT, Son CG, Westermann F, Berthold F, Schwab M, Catchpoole D, Khan J.
cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
BMC Genomics. 5: 70, 2004.
[Journal]
68)  Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, Greer BT, Son CG, Westermann F, Berthold F, Schwab M, Catchpoole D, Khan J.
cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
BMC Genomics. 70, 2004.
[Journal]
69)  Greer BT, Khan J.
Diagnostic classification of cancer using DNA microarrays and artificial intelligence.
Ann N Y Acad Sci. 1020: 49-66, 2004.
[Journal]
70)  Greer BT, Khan J.
Diagnostic classification of cancer using DNA microarrays and artificial intelligence.
Ann N Y Acad Sci. 1020: 49-66, 2004.
[Journal]
71)  Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G.
Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators.
Nat Med. 10: 175-81, 2004.
[Journal]
72)  Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M, Khan J.
Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma.
Cancer Res. 64: 6883-91, 2004.
[Journal]
73)  Kapetanovic IM, Umar A, Khan J.
Proceedings: the Applications of Bioinformatics in Cancer Detection Workshop.
Ann N Y Acad Sci. 1020: 1-9, 2004.
[Journal]
74)  Williams RD, Hing SN, Greer BT, Whiteford CC, Wei JS, Natrajan R, Kelsey A, Rogers S, Campbell C, Pritchard-Jones K, Khan J.
Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines.
Genes Chromosomes Cancer. Sep;41(1): 65-79, 2004.
[Journal]
75)  Desper R, Khan J, Schäffer AA.
Tumor classification using phylogenetic methods on expression data.
J Theor Biol. 228: 477-96, 2004.
[Journal]
76)  Bomprezzi R, Ringnér M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, Trent JM.
Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease.
Hum Mol Genet. 12: 2191-9, 2003.
[Journal]
77)  Khan J.
Genomic & proteomic technological advances in cancer research.
Pharmacogenomics. 4: 245-9, 2003.
[Journal]
78)  Ringnér M, Peterson C, Khan J.
Analyzing array data using supervised methods.
Pharmacogenomics. 3: 403-15, 2002.
[Journal]
79)  Dickens DS, Kozielski R, Khan J, Forus A, Cripe TP.
Cyclooxygenase-2 expression in pediatric sarcomas.
Pediatr Dev Pathol. 5: 356-64, 2002.
[Journal]
80)  Rice AM, Currier MA, Adams LC, Bharatan NS, Collins MH, Snyder JD, Khan J, Cripe TP.
Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis.
J Pediatr Hematol Oncol. Oct;24(7): 527-33, 2002.
[Journal]
81)  Khan J, Saal LH, Bittner ML, Jiang Y, Gooden GC, Glatfelter AA, Meltzer PS.
Gene expression profiling in cancer using cDNA microarrays.
Methods Mol Med. 68: 205-22, 2002.
[Journal]
82)  Khan J, Wei JS, Ringnér M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS.
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks.
Nat Med. 7: 673-9, 2001.
[Journal]
83)  Dupont J, Khan J, Qu BH, Metzler P, Helman L, LeRoith D.
Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis.
Endocrinology. 142: 4969-75, 2001.
[Journal]
84)  Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L.
Metastasis-associated differences in gene expression in a murine model of osteosarcoma.
Cancer Res. 61: 3750-9, 2001.
[Journal]
85)  Heiskanen MA, Bittner ML, Chen Y, Khan J, Adler KE, Trent JM, Meltzer PS.
Detection of gene amplification by genomic hybridization to cDNA microarrays.
Cancer Res. 60(4): 799-802, 2000.
[Journal]
86)  Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS.
cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene.
Proc Natl Acad Sci U S A. 96: 13264-9, 1999.
[Journal]
87)  Khan J, Bittner ML, Chen Y, Meltzer PS, Trent JM.
DNA microarray technology: the anticipated impact on the study of human disease.
Biochim Biophys Acta. 1423: M17-28, 1999.
[Journal]
88)  Khan J, Saal LH, Bittner ML, Chen Y, Trent JM, Meltzer PS.
Expression profiling in cancer using cDNA microarrays.
Electrophoresis. 20: 223-9, 1999.
[Journal]
89)  Khan J, Parsa NZ, Harada T, Meltzer PS, Carter NP.
Detection of gains and losses in 18 meningiomas by comparative genomic hybridization.
Cancer Genet Cytogenet. 103: 95-100, 1998.
[Journal]
90)  Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent JM, Meltzer PS.
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Cancer Res. 58: 5009-13, 1998.
[Journal]
91)  Khan J, Broadbent VA.
Tumor lysis syndrome complicating treatment of widespread metastatic abdominal rhabdomyosarcoma.
Pediatr Hematol Oncol. 10: 151-5, 1993.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 7/30/2014.